Statins, Fear Marketing, and the Problem With Anti-Medicine Influencers

We hear versions of the same story regularly. Someone has elevated cholesterol, an abnormal coronary calcium score, a strong family history, elevated lipoprotein(a), or another cardiovascular risk factor. Before the clinical discussion begins, they have encountered an online warning that statins are dangerous and are wondering whether their physician’s recommendation can be trusted.

The source may be a podcast, an Instagram reel, a wellness newsletter, or an account whose credentials suggest more clinical experience than the person actually has. The presentation is often persuasive because it contains something recognizable: a genuine adverse effect, a medication warning, or a patient’s difficult experience. Those details deserve attention, but their meaning depends on the evidence surrounding them and the circumstances of the person considering treatment.

A warning becomes misleading when it presents a possible adverse effect as an expected outcome, treats a personal experience as a reliable estimate of risk, or discourages treatment without addressing the consequences of leaving cardiovascular disease insufficiently managed. Patients can be left with a detailed account of what might go wrong with a medication and very little understanding of the condition it was prescribed to treat.

Lipid Treatment Begins With Cardiovascular Risk

At HormoneSynergy®, lipid management begins with the patient’s clinical circumstances. Someone with modest cholesterol elevation and few other risk factors may have a different treatment discussion from someone with a previous heart attack, substantial coronary plaque, severe hypercholesterolemia, diabetes, or chronic kidney disease. The expected benefit of treatment depends on both the degree of lipid reduction and the underlying likelihood of a cardiovascular event.

Nutrition, exercise, smoking cessation, blood pressure control, improved glucose regulation, and weight management when appropriate can meaningfully improve health. Their effect on LDL cholesterol and ApoB varies, however, and genetic influences can leave atherogenic lipoproteins elevated despite sustained healthy habits. Established atherosclerosis also changes the urgency and intensity of prevention.

Patients who develop symptoms may need a lower dose, a different statin, an alternative dosing schedule, or a non-statin medication. These adjustments are part of individualized care. They allow the clinician to pursue a tolerable treatment plan while keeping the original cardiovascular indication in view.

For more on atherogenic particle burden, see ApoB and Longevity: Cardiovascular Risk and Lipoprotein Particles. Our broader clinical approach is explained in Preventive Cardiology and Silent Heart Disease Detection.

What Changed in the 2026 Dyslipidemia Guideline?

The 2026 ACC/AHA multisociety guideline replaced the 2018 cholesterol guideline and updated recommendations for evaluating, treating, and monitoring lipid disorders. It emphasizes earlier attention to cumulative exposure to atherogenic lipoproteins, retains lifestyle as a foundation of care, and reintroduces specific LDL-C and non-HDL-C treatment goals according to cardiovascular risk.

For eligible adults undergoing primary prevention assessment, the guideline recommends the newer PREVENT-ASCVD equations. These estimates are then interpreted alongside information that may not be fully represented in a calculator, including premature cardiovascular disease in the family, chronic inflammatory conditions, reproductive history, and inherited lipid risk. Patients with established cardiovascular disease or certain other high-risk conditions require their own treatment pathways.

Lipoprotein(a) measurement is recommended at least once in adulthood. ApoB can add useful information in selected patients, particularly when the standard lipid profile may underestimate atherogenic particle burden or residual risk. This can be relevant when triglycerides are elevated, diabetes or cardiometabolic disease is present, or treated LDL cholesterol appears reassuring despite other concerning findings.

Coronary artery calcium scoring can help clarify an uncertain treatment decision by identifying calcified coronary plaque. Its interpretation depends on age, clinical history, and other risk factors. A calcium score of zero can be reassuring in appropriate circumstances, but it does not exclude noncalcified plaque or eliminate every reason to consider treatment.

These recommendations support a more complete discussion of cardiovascular prevention. Cholesterol measurements remain clinically important, but their interpretation is strengthened by understanding the patient’s risk over time, evidence of existing disease, and the benefit reasonably expected from intervention.

Interpreting the FDA Cognitive Warning

Statin labeling acknowledges rare post-marketing reports of memory loss, forgetfulness, confusion, and other cognitive symptoms. The reported symptoms have generally been nonserious and reversible after discontinuation. This information is relevant when evaluating a patient who notices a change after beginning treatment.

Post-marketing reports help identify potential adverse effects that warrant investigation. Because they are reported outside a controlled trial, they cannot by themselves establish causation or determine how frequently a symptom occurs. Other medications, sleep problems, mood disorders, vascular disease, and unrelated medical conditions may contribute to cognitive complaints.

Randomized trial evidence has not established that statins cause dementia. A 2025 systematic review and meta-analysis involving more than 100,000 participants found no statistically significant difference in incident dementia or cognitive impairment between lipid-lowering treatment and control over the available trial follow-up. The findings are reassuring, although the duration of those trials limits conclusions about effects over several decades.

Observational studies have sometimes associated statin use with lower dementia rates. Those associations are worth investigating, but differences in healthcare access, medication adherence, cardiovascular management, and other characteristics can influence the results. They do not establish statins as a treatment for preventing Alzheimer’s disease.

A new memory complaint should therefore receive an appropriate evaluation without assuming either that the statin caused it or that the medication could not be involved. Our discussion of the research continues in Statins and Alzheimer’s: What the Data Actually Shows.

Muscle Symptoms and the Nocebo Effect

Statin-associated muscle symptoms can occur, and rare serious muscle complications are recognized. Drug interactions can increase statin exposure, while thyroid disease, strenuous exercise, and other medical conditions can complicate the assessment. A patient describing pain or weakness after starting treatment deserves a review of the symptoms and the circumstances in which they developed.

Controlled studies also show that symptoms attributed to statins can arise during placebo treatment. In the SAMSON trial, patients who had previously stopped statins because of side effects received periods of atorvastatin, placebo tablets, and no tablets. Participants were blinded to whether the tablets contained atorvastatin or placebo, although they knew when they were taking no tablets.

Average symptom scores were similar during statin and placebo periods and lower during periods without tablets. Approximately 90% of the additional symptom burden during statin periods was reproduced during placebo periods. This finding describes the symptom pattern in that selected study population; it does not mean that 90% of every patient’s symptoms are imaginary or that genuine statin intolerance does not exist.

The nocebo effect refers to symptoms associated with the expectation of harm and the context of treatment rather than the medication’s pharmacologic action. Those symptoms are real. Understanding this effect can help clinicians explain why a supervised treatment adjustment or rechallenge may be informative, while continuing to investigate other potential causes.

Repeated warnings about muscle damage or brain fog can influence what a patient expects and how they interpret ordinary fluctuations in health. Clinical care should leave room for that possibility without using it to dismiss the person’s experience. We discuss these concerns further in Statins, Dementia & Side Effects: Separating Evidence From Influencer Myths.

Blood Glucose and Diabetes Risk

Statins can produce a small increase in blood glucose and increase the likelihood of a diabetes diagnosis, particularly with more intensive treatment. Many additional diagnoses occur among people whose glucose levels are already close to the diagnostic threshold. Insulin resistance, rising A1c, visceral adiposity, and other metabolic findings therefore deserve attention when treatment is being considered and monitored.

For a patient with a strong cardiovascular indication, this risk is generally addressed alongside lipid treatment rather than used as the sole reason to avoid it. The expected cardiovascular benefit, baseline metabolic vulnerability, and treatment intensity all belong in the discussion.

Nutrition, resistance training, aerobic activity, sleep, and body composition can support glucose regulation during treatment. Follow-up measurements allow the clinician to identify changes and respond appropriately. A patient with prediabetes should receive a coordinated metabolic and cardiovascular plan that explains how both areas will be managed.

Understanding Clinical Credentials

Useful health information comes from many disciplines, including medicine, pharmacy, nursing, nutrition, and research. A doctoral degree can represent substantial expertise, but the field of training and the scope of that expertise should be clear to the audience. A title alone does not establish experience diagnosing coronary disease, interpreting vascular imaging, prescribing lipid-lowering medication, or managing adverse effects.

Patients evaluating advice should be able to identify the person’s degree, relevant training, professional license when applicable, and experience in the area being discussed. Researchers may provide valuable analysis without treating patients, while licensed clinicians may work outside their principal area of expertise. Clear disclosure helps the audience understand what kind of authority a statement carries.

At HormoneSynergy®, Dr. Kathryn Retzler’s work in preventive longevity medicine includes more than 25 years of clinical experience and additional education in preventive cardiology. The clinical responsibility involves evaluating the individual patient, explaining recommendations, monitoring response, and adjusting care when symptoms or new findings arise.

We have explored the presentation of medical authority online in Fake Doctors, AI Health Groups, and Wellness Marketing, Fake Doctors, AI Profiles, and Medical Misinformation Online, and When Online Doctors Misrepresent Experience.

How Medical Risks Lose Their Context

Similar problems arise in discussions of mammography, colonoscopy, vaccines, blood pressure medication, hormone therapy, and diabetes treatment. A recognized limitation or adverse effect may be presented without information about its frequency, the population affected, or the benefit expected from the intervention. The audience receives enough information to become concerned but too little to make a well-informed decision.

Screening tests and medications deserve careful evaluation. Mammography can lead to false-positive findings and overdiagnosis. Colonoscopy carries procedural risks. Prescription treatments can cause adverse effects or be used in circumstances where the expected benefit is limited. Each intervention requires its own assessment of evidence, eligibility, alternatives, and patient preferences.

Commercial incentives also deserve scrutiny across pharmaceuticals, supplements, testing, and wellness services. The presence of a financial interest should prompt transparent disclosure and examination of the evidence. It does not, on its own, establish whether a treatment is effective or whether a recommendation is appropriate.

What a Cardiovascular Assessment Should Address

A useful assessment brings together LDL-C, non-HDL-C, blood pressure, smoking exposure, family history, diabetes, kidney function, and previous cardiovascular events. Lp(a) identifies an important inherited contributor to risk, while ApoB can help clarify atherogenic particle burden in selected patients. Evidence of coronary calcium or other arterial plaque adds information about disease that is already present.

The discussion should then explain what additional lipid lowering is expected to accomplish. Absolute benefit depends on the patient’s starting risk, and treatment recommendations should reflect that context. Symptoms, previous medication experiences, cost, access, and patient preferences influence which approach is practical.

At HormoneSynergy®, these findings are considered within a broader preventive assessment that may include glucose regulation, visceral fat, muscle mass, nutrition, exercise, sleep, and selected inflammatory markers. Hormone health may also be relevant to the wider clinical picture, although hormone treatment does not replace evidence-based cardiovascular prevention.

Testing is most useful when its result can inform a decision. Our Coronary Calcium Score vs. CCTA and Cleerly® Plaque Analysis guide explains the different questions these imaging approaches can answer.

Lifestyle Remains Part of Treatment

Nutrition, physical activity, smoking cessation, sleep, blood pressure, and metabolic health continue to influence cardiovascular risk after a statin is prescribed. Medication can address atherogenic lipoprotein exposure, but it cannot provide the full range of benefits associated with improved fitness, muscle preservation, adequate sleep, or better glucose regulation.

For some patients, sustained lifestyle changes may be sufficient to reach an acceptable risk level without medication. Others have inherited lipid disorders or established atherosclerosis that justify additional treatment. A healthy body weight, low triglycerides, or a regular exercise routine can be favorable findings while clinically important LDL or ApoB elevation remains.

A coordinated plan defines the role of each intervention and follows the response over time. Patients should understand which changes are expected to improve metabolic health, which treatments lower atherogenic lipoproteins, and how the clinician will assess progress.

When Symptoms Develop During Treatment

Evaluation may include the timing, severity, and distribution of symptoms; the statin and dose; other medications; thyroid function; recent exercise; and other potential causes. Laboratory testing is selected according to the clinical findings. Significant weakness or other concerning symptoms require prompt assessment.

Depending on the circumstances, a clinician may consider a lower dose, a different statin, less frequent dosing, or a supervised rechallenge. A tolerated statin dose can sometimes be combined with another medication to achieve the necessary lipid reduction. Patients with confirmed intolerance may need a non-statin regimen.

Ezetimibe, bempedoic acid, and PCSK9 monoclonal antibodies are evidence-based options in appropriate clinical settings. The choice depends on the reduction needed, cardiovascular history, tolerability, other medical conditions, and access. Follow-up testing helps determine whether the revised plan is achieving its intended effect.

Medicine, Not Marketing

Medicine, Not Marketing requires a clear explanation of why treatment is being recommended, what benefit is reasonably expected, and how potential harms will be monitored. It also requires taking patient experiences seriously and revisiting a plan when the response differs from what was anticipated.

Cardiovascular risk reflects cumulative exposure to atherogenic lipoproteins, blood pressure, smoking, metabolic disease, kidney disease, genetics, and other influences. Prevention becomes more useful when those findings are interpreted together and the patient understands how each recommendation addresses them.

Dr. Kathryn Retzler’s approach combines attention to measurable cardiovascular risk with the ongoing work of improving nutrition, physical function, sleep, and metabolic health. Patients should leave the discussion with a treatment plan they understand, a way to report concerns, and a clear expectation for follow-up.

---

Frequently Asked Questions

Are statins dangerous?

Statins can cause adverse effects, but they also reduce cardiovascular events in appropriately selected patients. Whether treatment is appropriate depends on cardiovascular risk, expected benefit, other medical conditions, tolerance, and patient preferences.

Do statins cause dementia?

Randomized trial evidence has not established that statins cause dementia. Statin labeling acknowledges rare reports of generally nonserious and reversible cognitive symptoms. A new memory complaint deserves evaluation, and observational associations with lower dementia rates do not establish that statins prevent Alzheimer’s disease.

Can statins cause muscle pain?

Yes. Statin-associated muscle symptoms can occur, although symptoms during treatment can also have other causes. Placebo-controlled studies show that treatment expectations can contribute to symptom burden. Evaluation should consider the medication, dose, interactions, exercise, thyroid health, and other clinical findings.

Can statins increase blood sugar?

Statins can slightly increase blood glucose and the likelihood of a diabetes diagnosis, particularly among people already near the diagnostic threshold. When the cardiovascular indication is strong, clinicians generally address metabolic risk and monitoring alongside treatment rather than avoid an otherwise appropriate statin solely for this reason.

What does the 2026 guideline say about ApoB and lipoprotein(a)?

The guideline recommends measuring lipoprotein(a) at least once in adulthood. ApoB testing can add information in selected patients when standard cholesterol measurements may underestimate atherogenic particle burden or residual cardiovascular risk.

Should I stop a statin because of something I saw online?

An online claim should prompt a discussion with the prescribing clinician rather than an unsupervised treatment change. Review the reason for treatment, expected benefit, symptoms, interactions, and available alternatives. Significant or concerning symptoms warrant prompt medical assessment.

Longevity Medicine Education Series
This article is part of the HormoneSynergy® Longevity Medicine education series covering preventive cardiology, metabolic health, hormone optimization, body composition, and advanced diagnostics for healthy aging.

Return to the Longevity Medicine Guide →